medigraphic.com
Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán

2023, Number 3

<< Back Next >>

Rev Biomed 2023; 34 (3)

Topical treatment of cutaneous leishmaniasis using a nanoemulsion cream-based on generic pentavalent antimony. Case report

Añez N, Bullón J, Crisante G, Scorza-Dagert JV, Véjar F, Forgiarini A

Language: English
References: 15
Page: 317-321
PDF size: 156.01 Kb.


ABSTRACT

Introduction. An effective vaccine against cutaneous leishmaniasis has yet to be developed. Treatment of the disease relies on painful intramuscular administration of high doses of compounds based on pentavalent antimony, causing adverse effects. New therapeutic options effective, easy to apply, cheap and without adverse effects are urgently required.
Case report. A 26-year-old male patient showing a large facial ulcer, presumptively by cutaneous leishmaniasis, diagnostic confirmed by Montenegro’s skin test and microscopical observation of amastigote forms. Due to the ulcer’s location and size, topical treatment with a nanoemulsion cream-based on a generic antimonycompound was attempted. The cream was applied twice daily and was rapidly absorbed. After 2 months of treatment, no discomfort or other adverse effects were detected. The ulcer was replaced with healthy skin tissue and a soft, clean scar.
Conclusion. The novel cream, which was rapidly absorbed, effective, cheaper than standard systemic therapy and self-applied by the patient, showed potential value in the treatment of cutaneous leishmaniasis.


REFERENCES

  1. Añez N, Nieves E, Cazorla D, Oviedo M, de YarbuhAL, Valera M. Epidemiology of cutaneous leishmaniasisin Mérida, Venezuela. III. Altitudinal distribution, agestructure, natural infection and feeding behavior ofsandflies and their relation to the risk of transmission.Ann Trop Med Parasitol. 1994; 88:279–287. https://doi.org/10.1080/00034983.1994.11812868

  2. Chaves LF, Añez N. Species co-occurrence andfeeding behavior in sand fly transmission of Americancutaneous leishmaniasis in western Venezuela. ActaTrop. 2004; 92:219–224. https://doi.org/10.1016/j.actatropica.2004.08.001.

  3. Torrellas A, Ferrer E, Cruz I, de Lima H, DelgadoO, Carrero J, et al. Molecular typing reveals the coexistenceof two transmission cycles of Americancutaneous leishmaniasis in the Andean Region ofVenezuela with Lutzomyia migonei as the vector. MemInst Oswaldo Cruz. 2018;113(12):e180323. https://doi.org/10.1590/0074-02760180323.

  4. Scorza-Dagert JV, Morales C, Petit de Peña Y, VásquezE, Rojas E, Scorza JV. Síntesis de un complejo antimonialpentavalente (Ulamina) y su aplicación experimentalpara el tratamiento de leishmaniasis cutánea localizadaen Venezuela. Bol Malariol Sal Amb. 2006; 46(1):59-65.

  5. Almeida R, Brito J, Machado P, de Jesus A, Schriefer A,Guimarães LH et al. Successful treatment of refractorycutaneous leishmaniasis with GM-CSF and antimonials.Am J Trop Med Hyg. 2005;73(1):7981.

  6. Vásquez LC, Scorza-Dagert JV, Scorza JV, Vicuña-Fernández N, Petit de Peña Y, López P, et al.Pharmacokinetics of experimental pentavalent antimonyafter an intramuscular administration in adult volunteers.Cur Ther Res Clin Exp. 2006; 67: 193-203.

  7. Lindoso JAL, Costa JML, Queiroz IM, Goto H. Reviewof the current treatments for leishmaniasis. Res Rep TropMed. 2012; 3:69–77. https://doi.org/10.2147/RRTM.S24764.

  8. Duque MC, Vasconcellos EC, Pimentel MI, Lyra MR,Pacheco SJ, et al. Standardization of intralesionalmeglumine antimoniate treatment for cutaneousleishmaniasis. Rev Soc Bras Med Trop. 2016;49(6):774–776.

  9. Añez N, Rojas A, Scorza-Dagert JV, Morales C.Successful treatment against American cutaneousleishmaniasis by intralesional infiltration of a genericantimonial compound-lidocaine combination. A followup study. Acta Trop. 2018; 185: 261–266. https://doi.org/10.1016/j.actatropica.2018.06.001.

  10. Bullón J, Márquez L, Fernández JA, Scorza C, Scorza-Dagert JV, Rodríguez J, et al. A Promising CutaneousLeishmaniasis Treatment with a Nanoemulsion-BasedCream with a Generic Pentavalent Antimony (Ulamina)as the Active Ingredient. Cosmetics. 2021; 8(115): 2-17.https://doi.org/10.3390/ cosmetics8040115.

  11. WHO Expert Committee on the Control of theLeishmaniases & World Health Organization. Controlof the leishmaniases: Report of a Meeting of the WHOExpert Committee on the Control of Leishmaniases,Geneva, Switzerland, 22–26 March 2010; World HealthOrganization: Geneva, Switzerland.

  12. Roberts M, Cross S, Pellett M. Skin Transport. In:Dermatological and Transdermal Formulations, 1st ed.;Walters, K.A., Ed.; CRC Press, Taylor & Francis: NewYork, NY, USA 2002.

  13. Magnusson BM, Anissimov Y, Cross S, Roberts M.Molecular Size as the Main Determinant of SoluteMaximum Flux Across the Skin. J Investig Dermatol.2004; 122:993–999, https://doi.org/10.1111/j.0022-202x.2004.22413.x.

  14. Rodrigues LN, Zanluchi JM, Grebogi IH. Percutaneousabsorption enhancers: Mechanisms and potential. BrasArch Biol Technol. 2007; 50:949–961, https://doi.org/10.1590/s1516-89132007000700006.

  15. Leite-Silva VR, de Almeida MM, Fradin A, Grice J,Roberts M. Delivery of drugs applied topically to theskin. Expert Rev Dermatol. 2012; 7:383–397, https://doi.org/10.1586/edm.12.32.




2020     |     www.medigraphic.com